Product Pipeline

LYR-210 for Chronic Rhinosinusitis

Our lead product candidate, entering Phase 2, is LYR-210 for chronic rhinosinusitis (CRS).

Lyra’s lead product candidate, entering Phase 2, is LYR-210 for chronic rhinosinusitis (CRS), an inflammatory disease of the nasal passages. LYR-210 is a proprietary therapeutic that uses Lyra’s transmucosal therapeutic system to deliver a custom long-acting formulation of mometasone fuorate, a proven steroid, deep into the sinonasal tissue.

LYR-210’s unique therapeutic properties enable it to address the challenges of CRS. Clinical results evaluating LYR-210 in CRS patients have shown LYR-210 to be safe and well-tolerated and demonstrated significant improvements in clinical outcomes in patients with CRS.

LYR-210 has the potential to be one of the first approved drug products for CRS and is the only product in development offering six months of continuous drug therapy with a single administration.

For a summary of the results from the Phase 1 clinical study of LYR-210 in CRS, please see the announcement of the clinical data at the American Rhinologic Society Annual Meeting in October 2018.

Douglas RG, Psaltis AJ, Rimmer J, Kuruvilla T, Cervin A, and Kuang Y. Phase 1 clinical study to assess the safety of a novel drug delivery system providing long-term topical steroid therapy for chronic rhinosinusitis International Forum of Allergy & Rhinology, Vol. 9, No. 4, April 2019.